MCID: BLD047
MIFTS: 38

Bladder Squamous Cell Carcinoma malady

Categories: Cancer diseases, Skin diseases, Nephrological diseases

Aliases & Classifications for Bladder Squamous Cell Carcinoma

Aliases & Descriptions for Bladder Squamous Cell Carcinoma:

Name: Bladder Squamous Cell Carcinoma 12 14 69
Epidermoid Carcinoma of the Urinary Bladder 12
Squamous Cell Carcinoma of Bladder 12
Carcinoma Squamous Cell Bladder 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3742
NCIt 47 C4031
SNOMED-CT 64 255111004
UMLS 69 C0279681

Summaries for Bladder Squamous Cell Carcinoma

Disease Ontology : 12 A carcinoma of bladder that is manifested in squamous cells of the bladder.

MalaCards based summary : Bladder Squamous Cell Carcinoma, also known as epidermoid carcinoma of the urinary bladder, is related to squamous cell carcinoma and fetishism, and has symptoms including dysuria An important gene associated with Bladder Squamous Cell Carcinoma is S100A7 (S100 Calcium Binding Protein A7), and among its related pathways/superpathways are Glioma and Development HGF signaling pathway. The drugs Epirubicin and Fentanyl have been mentioned in the context of this disorder. Related phenotypes are muscle and neoplasm

Related Diseases for Bladder Squamous Cell Carcinoma

Diseases related to Bladder Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
id Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 10.3
2 fetishism 10.3 CDKN2A UPK2
3 anal neuroendocrine tumor 10.2 CDKN2A HGF
4 common variable immunodeficiency 10.2 FGF2 HGF
5 acute disseminated encephalomyelitis 10.1 CDKN2A PTEN
6 brachydactyly tibial hypoplasia 10.1 CDKN2A PTGS2
7 immature teratoma of ovary 10.1 FGF2 PTEN
8 clear cell adenofibroma 10.1 CDKN2A TP53
9 lacrimal gland adenoid cystic carcinoma 10.1 CDKN2A TP53
10 pericardium leiomyoma 10.1 CDKN2A TP53
11 spondylarthropathy 10.1 CDKN2A TP53
12 active vestibular meniere's disease 10.1 CDKN2A PTGS2
13 lacrimal gland squamous cell carcinoma 10.1 CDKN2A TP53
14 endometrial squamous cell carcinoma 10.0 CDKN2A TP53
15 glomeruloid hemangioma 10.0 CDKN2A FGF2 PTEN
16 ampulla of vater neoplasm 10.0 CDKN2A TP53
17 coccidiosis 10.0 CDKN2A TP53
18 anal carcinoma in situ 10.0 CDKN2A TP53 UPK2
19 estrogen-receptor positive breast cancer 10.0 CDKN2A S100A7 TP53
20 nasal cavity cancer 10.0 FGF2 HGF PTGS2
21 breast ductal carcinoma 10.0 PTEN TP53
22 postpoliomyelitis syndrome 10.0 CDKN2A TP53
23 bile duct clear cell adenocarcinoma 10.0 PTGS2 TP53
24 epididymis adenocarcinoma 10.0 HGF PTEN PTGS2
25 paraphimosis 9.9 CDKN2A TP53
26 flat ductal epithelial atypia 9.9 CDKN2A FGF2 TP53
27 adult syndrome 9.9 PTEN TP53
28 oro-mandibular-limb hypogenesis syndrome 9.9 CDKN2A TP53
29 uterine disease 9.9 CDKN2A TP53
30 villoglandular endometrial endometrioid adenocarcinoma 9.9 PTEN TP53
31 myxedema 9.9 CDKN2A PTEN TP53
32 interstitial lung disease 9.9 CDKN2A PTEN TP53
33 marginal zone b-cell lymphoma 9.9 CDKN2A PTEN TP53
34 nasopharyngeal carcinoma 9.9 CDKN2A PTEN TP53
35 trachea squamous cell carcinoma 9.9 CDKN2A PTEN TP53
36 adult oligodendroglioma 9.9 CDKN2A PTEN TP53
37 hepatic flexure cancer 9.9 CDKN2A PTEN TP53
38 transitional cell carcinoma 9.9
39 bardet-biedl syndrome 9.9 CDKN2A PTEN TP53
40 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 9.9 CDKN2A PTEN TP53
41 acquired hemangioma 9.9 CDKN2A PTGS2 TP53
42 tamoxifen-related endometrial lesion 9.9 CDKN2A PTGS2 TP53
43 autonomic nervous system neoplasm 9.9 CDKN2A PTEN TP53
44 advanced sleep phase syndrome 9.9 CDKN2A PTGS2 TP53
45 mitochondrial encephalomyopathy 9.9 CDKN2A PTGS2 TP53
46 fallopian tube adenocarcinoma 9.9 CDKN2A PTGS2 TP53
47 alpha chain disease 9.9 CDKN2A PTGS2 TP53
48 dysembryoplastic neuroepithelial tumor 9.9 PTGS2 TP53 UPK2
49 ornithinemia 9.9 CDKN2A PTGS2 TP53
50 spinal muscular atrophy with progressive myoclonic epilepsy 9.8 CDKN2A PTGS2 TP53

Graphical network of the top 20 diseases related to Bladder Squamous Cell Carcinoma:



Diseases related to Bladder Squamous Cell Carcinoma

Symptoms & Phenotypes for Bladder Squamous Cell Carcinoma

UMLS symptoms related to Bladder Squamous Cell Carcinoma:


dysuria

MGI Mouse Phenotypes related to Bladder Squamous Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.43 PTGS2 TP53 CDKN2A FGF2 HMBS PTEN
2 neoplasm MP:0002006 9.02 CDKN2A FGF2 PTEN PTGS2 TP53

Drugs & Therapeutics for Bladder Squamous Cell Carcinoma

Drugs for Bladder Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Fluorouracil Approved Phase 3 51-21-8 3385
4
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
5 interferons Phase 3,Phase 1,Phase 2
6 Alkylating Agents Phase 3,Phase 2
7 Mitomycins Phase 3
8 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
9 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
10 Nucleic Acid Synthesis Inhibitors Phase 3
11 Vaccines Phase 3,Phase 1,Phase 2
12 Pharmaceutical Solutions Phase 3
13 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
14 Anti-Infective Agents Phase 3,Phase 2,Phase 1
15 Interferon-alpha Phase 3
16 Liver Extracts Phase 3,Phase 2,Phase 1
17 Antibiotics, Antitubercular Phase 3,Phase 2
18 BCG Vaccine Phase 3
19 Antiviral Agents Phase 3,Phase 2,Phase 1
20 pancreatic polypeptide Phase 3
21 Analgesics Phase 3
22 Adjuvants, Anesthesia Phase 3
23 Narcotics Phase 3
24 Analgesics, Opioid Phase 3
25 Anesthetics Phase 3
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Peripheral Nervous System Agents Phase 3
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
30 Antimetabolites Phase 3,Phase 2,Phase 1
31 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
32 Antimitotic Agents Phase 3,Phase 2,Phase 1
33 Central Nervous System Depressants Phase 3
34 Cola Nutraceutical Phase 3,Phase 2,Phase 1
35
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
36
Indinavir Approved Phase 2 150378-17-9 5362440
37
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
38
Etoposide Approved Phase 2 33419-42-0 36462
39
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
40
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
41
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
42
Ifosfamide Approved Phase 2 3778-73-2 3690
43
Trastuzumab Approved, Investigational Phase 2,Phase 1 180288-69-1 9903
44
Mechlorethamine Approved Phase 2 51-75-2 4033
45
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
46
Lenograstim Approved Phase 2,Phase 1 135968-09-1
47
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Everolimus Approved Phase 2 159351-69-6 6442177
50
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 57)
id Name Status NCT ID Phase
1 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
4 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
5 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
6 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
7 Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Completed NCT00005831 Phase 2
8 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
9 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2
10 S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Completed NCT00055835 Phase 2
11 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2
12 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2
13 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2
14 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2
15 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
16 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
17 Genetic Predictors of Benefit to Pembrolizumab Recruiting NCT02710396 Phase 2
18 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Recruiting NCT02001623 Phase 1, Phase 2
19 Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Recruiting NCT02646319 Phase 2
20 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2
21 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
22 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2
23 Cabozantinib for Advanced Urothelial Cancer Active, not recruiting NCT01688999 Phase 2
24 Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma Not yet recruiting NCT03174275 Phase 2
25 Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer Terminated NCT01611662 Phase 2
26 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2
27 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2
28 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder Unknown status NCT01124682 Phase 1
29 Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment Completed NCT00016237 Phase 1
30 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
31 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
32 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1
33 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1
34 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
35 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1
36 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
37 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
38 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
39 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1
40 Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors Recruiting NCT02636036 Phase 1
41 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) Recruiting NCT01772004 Phase 1
42 Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Recruiting NCT02315066 Phase 1
43 Safety Study of MGA271 in Refractory Cancer Recruiting NCT01391143 Phase 1
44 Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Recruiting NCT02432963 Phase 1
45 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting NCT02628535 Phase 1
46 MAGE-A4ᶜ¹º³²T for Multi-Tumor Recruiting NCT03132922 Phase 1
47 Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Terminated NCT00072137 Phase 1
48 Safety Study of AMG 228 to Treat Solid Tumors Terminated NCT02437916 Phase 1
49 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
50 Comparison of Tomotherapy Versus Intensity-modulated Step-and-shoot and Conventional Radiation Treatment Plans for Patients With Locally-advanced Squamous Cell Carcinoma of the Cervix Completed NCT00124488

Search NIH Clinical Center for Bladder Squamous Cell Carcinoma

Genetic Tests for Bladder Squamous Cell Carcinoma

Anatomical Context for Bladder Squamous Cell Carcinoma

Publications for Bladder Squamous Cell Carcinoma

Articles related to Bladder Squamous Cell Carcinoma:

(show all 17)
id Title Authors Year
1
Risk factors for development of primary bladder squamous cell carcinoma. ( 27869492 )
2016
2
Bladder squamous cell carcinoma in pregnancy. ( 26467844 )
2015
3
Vesicoenteric fistula due to bladder squamous cell carcinoma. ( 25045451 )
2014
4
Radiation treatment of bladder squamous cell carcinoma in a patient with spina bifida: A case report. ( 22709884 )
2012
5
p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. ( 22684221 )
2012
6
Urinary schistosomiasis with simultaneous bladder squamous cell carcinoma and transitional cell carcinoma. ( 23109968 )
2012
7
Enterovesical fistula caused by a bladder squamous cell carcinoma. ( 19725163 )
2009
8
Bladder squamous cell carcinoma. ( 15143234 )
2004
9
Bladder squamous cell carcinoma biomarkers derived from proteomics. ( 10892722 )
2000
10
Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. ( 10197442 )
1999
11
Enhanced tumorigenicity of rat bladder squamous cell carcinoma cells after abrogation of gap junctional intercellular communication. ( 9685850 )
1998
12
Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. ( 9515818 )
1998
13
Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. ( 9307301 )
1997
14
Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. ( 8618345 )
1996
15
Bladder squamous cell carcinoma with human papilloma virus type 6 [HPV 6]. ( 8749958 )
1995
16
UNME/K1: an IgG2a monoclonal antibody specific to cytokeratin of human urinary bladder squamous cell carcinoma. ( 1712997 )
1991
17
Dramatic palliation for painful, fixed bladder squamous cell carcinoma with 5-fluorouracil infusion. ( 71361 )
1977

Variations for Bladder Squamous Cell Carcinoma

Cosmic variations for Bladder Squamous Cell Carcinoma:

9 (show all 39)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10812 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.722C>T p.S241F 15
2 COSM45286 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.475G>T p.A159S 15
3 COSM44117 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.775G>A p.D259N 15
4 COSM10790 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.455C>T p.P152L 15
5 COSM10648 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.524G>A p.R175H 15
6 COSM10709 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.722C>G p.S241C 15
7 COSM45248 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.805A>T p.S269C 15
8 COSM10719 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.811G>A p.E271K 15
9 COSM44451 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.874A>G p.K292E 15
10 COSM10722 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.853G>A p.E285K 15
11 COSM43963 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.396G>C p.K132N 15
12 COSM45285 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.795G>C p.L265L 15
13 COSM44950 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.862A>G p.N288D 15
14 COSM11491 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.743G>C p.R248P 15
15 COSM43660 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.719G>T p.S240I 15
16 COSM10810 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.725G>T p.C242F 15
17 COSM44469 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.812A>T p.E271V 15
18 COSM45138 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.853G>C p.E285Q 15
19 COSM45284 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.813G>A p.E271E 15
20 COSM44525 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.709A>G p.M237V 15
21 COSM43565 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.857A>G p.E286G 15
22 COSM10660 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.818G>A p.R273H 15
23 COSM10705 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.586C>T p.R196* 15
24 COSM10704 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.844C>T p.R282W 15
25 COSM10654 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.637C>T p.R213* 15
26 COSM10738 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.542G>A p.R181H 15
27 COSM44603 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.835G>A p.G279R 15
28 COSM45293 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.407A>G p.Q136R 15
29 COSM10801 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.404G>A p.C135Y 15
30 COSM44023 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.560G>A p.G187D 15
31 COSM46303 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.1031T>G p.L344R 15
32 COSM44091 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.746G>A p.R249K 15
33 COSM10728 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.839G>A p.R280K 15
34 COSM44202 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.550G>T p.D184Y 15
35 COSM45299 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.831T>G p.C277W 15
36 COSM763 PIK3CA urinary tract,bladder,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 15
37 COSM488 HRAS urinary tract,bladder,carcinoma,squamous cell carcinoma c.37G>T p.G13C 15
38 COSM19500 CDH1 urinary tract,bladder,carcinoma,squamous cell carcinoma c.2537G>C p.S846T 15
39 COSM550 KRAS urinary tract,bladder,carcinoma,undifferentiated carcinoma c.181C>G p.Q61E 12

Expression for Bladder Squamous Cell Carcinoma

Search GEO for disease gene expression data for Bladder Squamous Cell Carcinoma.

Pathways for Bladder Squamous Cell Carcinoma

Pathways related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 CDKN2A FGF2 HGF PTEN TP53
2
Show member pathways
12.55 HGF PTEN PTGS2 TP53
3
Show member pathways
12.46 FGF2 HGF PTEN TP53
4 12.27 FGF2 HGF PTEN TP53
5 12.1 CDKN2A PTEN PTGS2 TP53
6 11.82 CDKN2A PTEN TP53
7 11.79 HGF PTEN TP53
8 11.71 CDKN2A PTEN TP53
9 11.7 CDKN2A FGF2 HGF PTEN PTGS2 TP53
10 11.68 CDKN2A PTEN TP53
11 11.61 CDKN2A PTEN TP53
12 11.37 FGF2 HGF PTGS2
13 11.31 FGF2 HGF PTGS2 TP53
14 11.26 PTEN PTGS2 TP53
15 10.89 CDKN2A TP53
16
Show member pathways
10.88 CDKN2A TP53

GO Terms for Bladder Squamous Cell Carcinoma

Biological processes related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.73 FGF2 HGF PTEN PTGS2
2 negative regulation of cell proliferation GO:0008285 9.71 CDKN2A PTEN PTGS2 TP53
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.63 FGF2 PTEN S100A7
4 positive regulation of apoptotic process GO:0043065 9.62 CDKN2A PTEN PTGS2 TP53
5 cellular response to hypoxia GO:0071456 9.54 PTEN PTGS2 TP53
6 Ras protein signal transduction GO:0007265 9.33 CDKN2A FGF2 TP53
7 replicative senescence GO:0090399 9.26 CDKN2A TP53
8 phosphatidylinositol-mediated signaling GO:0048015 9.26 FGF2 HGF PTEN TP53
9 angiogenesis GO:0001525 9.02 ANG FGF2 PTEN PTGS2 S100A7

Molecular functions related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chemoattractant activity GO:0042056 8.62 FGF2 HGF

Sources for Bladder Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....